Aptose Biosciences (TSE:APS) Upgraded at Alliance Global Partners

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) was upgraded by stock analysts at Alliance Global Partners to a “strong-buy” rating in a note issued to investors on Thursday,Zacks.com reports.

Aptose Biosciences Trading Down 7.2 %

Shares of APS opened at C$4.36 on Thursday. The company has a debt-to-equity ratio of -117.37, a quick ratio of 5.41 and a current ratio of 1.05. The company has a market cap of C$187.73 million, a price-to-earnings ratio of -0.87 and a beta of 1.36. The stock has a fifty day moving average price of C$8.67 and a two-hundred day moving average price of C$12.27. Aptose Biosciences has a 52-week low of C$0.16 and a 52-week high of C$5.29.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.